Mazanti-Andersen advises FluoGuide on its SEK 75 million directed share issue

On 12 May 2021, FluoGuide announced the successful completion of a directed issue of 789,474 new shares at a price of SEK 95 per share, raising gross proceeds of SEK 75 million. The vast majority of the issue was subscribed by domestic and international long-only investors with support from existing large shareholders.

FluoGuide’s primary focus is to maximize surgical outcomes in oncology. It develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

Fluoguide intends to use the proceeds from the issue for one phase II study with the lead product FG001 in new prevalent indications in 2021, for preparation of a phase III study in 2022 and for preclinical studies on FG002.

Mazanti Transactions acted as Danish legal advisor to FluoGuide in connection with the transaction with a team led by partner Lars Lüthjohan Jensen.

Skandinaviska Enskilda Banken AB and ABG Sundal Collier acted as Joint Bookrunners and Sedermera Fondkommission acted as Co-Manager in connection with the transaction.